Hubei Cancer Hospital ( Site 3211)

Wuhan, Hubei 430079

0 studies enrolling now · 1 studies all time

What they study most

Breast Cancer

Studies at this site

• Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756) — Running, not enrolling